This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Methylene Blue for Vasoplegic Syndrome After Cardiac Operation: Early Administration Improves Survival
Mehaffey and colleagues evaluated major adverse events in 118 cardiopulmonary bypass (CPB) patients who had received methylene blue (MB) within 72 hours of CPB. Although these patients had high incidence of comorbidities and postoperative complications, MB administration in the operating room was associated with reduced operative mortality rate and incidence of adverse events compared to MB administration in the intensive care unit.